Key result
Screening of 2271 small molecules identified 120 compounds, including 7 highly effective CYP1 inhibitors, that prevent doxorubicin-induced cardiotoxicity in a zebrafish model.
Why the study?
Doxorubicin use is limited by cardiotoxicity and heart failure risk, prompting efforts to identify novel therapeutic targets for cardioprotection.
Does CYP1 inhibition prevent doxorubicin-induced cardiotoxicity in a zebrafish model?
Population
Zebrafish model of doxorubicin-induced cardiomyopathy
Comparison
Screening of 2271 small molecules and genetic mutation of cyp1a
Design
Preclinical small-molecule screening and genetic study
Authors
Loading...
CYP1 inhibition may mitigate doxorubicin cardiotoxicity; leaves open translation beyond zebrafish to mammalian or clinical settings.
Does CYP1 inhibition prevent doxorubicin-induced cardiotoxicity in a zebrafish model?
CYP1 inhibition prevents doxorubicin-induced cardiotoxicity in a zebrafish model, highlighting the CYP1 pathway as a potential therapeutic target for clinical cardioprotection.
Lam et al. (2020) studied Doxorubicin-induced cardiomyopathy. CYP1 inhibitors was evaluated on Prevention of doxorubicin-induced cardiotoxicity. Screening of 2271 small molecules identified 120 compounds, including 7 highly effective CYP1 inhibitors, that prevent doxorubicin-induced cardiotoxicity in a zebrafish model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: